Diviner Therapeutics is a cutting-edge biotechnology company based in Fairfax, VA, dedicated to developing innovative small molecule technology for the treatment of cancer. Their groundbreaking research focuses on the development of SD133, a first-in-class small molecule inhibitor that targets CDH11, a novel cancer target, and has shown promising results in increasing the survival rate of animals with pancreatic cancer.
With funding from prestigious organizations such as the National Institutes of Health (NIH), the Department of Defense (DoD), NIH SBIR awards, and strategic partnerships, Diviner Therapeutics is at the forefront of drug development. Led by a team of experienced scientists, including co-founders Dr. Sivanesan Dakshanamurthy and Dr. Stephen W Byers, the company is actively engaged in advanced preclinical studies to bring tomorrow's therapies to patients today.
Generated from the website